Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
January 16, 2024 16:05 ET
|
Allogene Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
Allogene Therapeutics and Foresight Diagnostics Announce Partnership to Develop MRD-based In-Vitro Diagnostic for Use in ALPHA3, the First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma
January 04, 2024 16:15 ET
|
Allogene Therapeutics, Inc.; Foresight Diagnostics
Partnership Will Utilize Foresight’s Ultra-Sensitive MRD Technology to Identify Patients for Enrollment in Allogene’s ALPHA3 Trial SAN FRANCISCO and BOULDER, Colo., Jan. 04, 2024 (GLOBE NEWSWIRE)...
Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of CAR T Led by ALPHA3, the Industry's First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma
January 04, 2024 16:05 ET
|
Allogene Therapeutics, Inc.
Four Core Programs Leverage Unique Attributes in Product Development and Trial Design to Demonstrate the Unmatched Potential of an Allogeneic CAR T Large B-Cell Lymphoma (LBCL): Groundbreaking ALPHA3...
Allogene Therapeutics to Host Conference Call Previewing its 2024 Platform Vision and Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024 16:05 ET
|
Allogene Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
Allogene Therapeutics Presents Comprehensive Safety Data of Proprietary Lymphodepletion Agent ALLO-647 at the 65th Annual Meeting of the American Society of Hematology
December 09, 2023 12:00 ET
|
Allogene Therapeutics, Inc.
Comprehensive Review of All Patients in the Phase 1 ALPHA/ALPHA2 Trials Demonstrate that Adding Investigational ALLO-647 to Standard Lymphodepletion Can Yield Durable Responses and a Safety Profile...
Allogene Therapeutics Announces Participation in December Investor Conference
December 01, 2023 08:30 ET
|
Allogene Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
Allogene Therapeutics Presents Preclinical Data on a Novel Allogeneic CAR T Product Candidate Targeting Claudin18.2 at the Society for Immunotherapy of Cancer Annual Meeting
November 03, 2023 12:00 ET
|
Allogene Therapeutics, Inc.
Research Provides Early Validation of ALLO-182, an AlloCAR T™ Candidate in the IND-Enabling Phase of Development Targeting Claudin18.2 for the Treatment of Patients with Gastric and Pancreatic Cancers...
Allogene Therapeutics Presents Preclinical Data on Next Generation Cloak™ and Dagger™ Technologies at the Society for Immunotherapy of Cancer Annual Meeting
November 03, 2023 12:00 ET
|
Allogene Therapeutics, Inc.
Cloak™ and Dagger™ Technologies Show Potential to Reduce Dependence on Standard Lymphodepletion and Enhance Performance of AlloCAR T™ CellsData from Preclinical Study of Cloak™ Technology Highlights...
Allogene Therapeutics Reports Third Quarter 2023 Financial Results and Business Update
November 02, 2023 16:02 ET
|
Allogene Therapeutics, Inc.
Preclinical Posters to Be Presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting on the Next Generation AlloCAR T™ Platform Cloak ™ and Dagger™ Technologies Highlighted Potential...
Allogene Therapeutics Announces Poster Presentations at the 65th Annual Meeting of the American Society of Hematology
November 02, 2023 09:00 ET
|
Allogene Therapeutics, Inc.
Comprehensive Review of Overall Treatment Safety Profile of our ALLO-501/501A Candidate Used in Conjunction with Propriety Lymphodepletion with Investigational ALLO-647 from the Phase 1 ALPHA/ALPHA2...